FDA Inspection
Novartis Pharmaceuticals CorporationNovartis Pharmaceuticals Corporation – FDA Inspection, Apr 7, 2017
Record Details
This FDA Inspection record concerns Novartis Pharmaceuticals Corporation, with an inspection on April 7, 2017, issued by the New Jersey District Office, covering biologics.
View Company Profile
ID · 9ab30769-64e6-41c7-bcc0-e04710bf5034
Inspection Facts
- Inspection number
- 1019194
- FDA center
- Biologics
- Outcome
- Form 483 issued
Other FDA inspections of Novartis Pharmaceuticals Corporation
4| Date | Classification | Office | Project area |
|---|---|---|---|
| February 6, 2026 | Not classified | New Jersey District Office | Human Cellular, Tissue, and Gene Therapies |
| August 8, 2024 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
| December 9, 2022 | NAI | Center for Biologics Evaluation and Research | Vaccines and Allergenic Products |
| August 21, 2019 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
Other documents for Novartis Pharmaceuticals Corporation
- FDA Inspection 1300144 - 2026-02-06
- FDA Inspection 1245942 - 2024-08-08
- FDA Inspection 1194474 - 2022-12-09
- FDA Inspection 1100101 - 2019-08-21
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.